entertainment -WSS

entertainment

author：explore 2025-09-29 16:35:02 - browse：773

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： New Alzheimer's drugs heat up race for early detection blood tests

explore

entertainment

WSS

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Medicare isn't yet testing food as medicine

Study fuels hope CAR

UHS says company favors patients whose insurance pays more

What it's like to live with paralysis for one psychologist

Color Health wants to make cancer screenings convenient

leisure time

entertainment

hotspot

The high cost of giving birth even with insurance

Will the FTC rein in IQVIA's health data empire?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare isn't yet testing food as medicine

Peter Hotez and the public health issue of online harassment

CDC advisory group OKs chikungunya vaccine

Apple is now the first public company to be valued at $3 trillion

UHS says company favors patients whose insurance pays more

Bright Health sells Medicare Advantage business to Molina

CDC Director Mandy Cohen on transparency, trust, and health

entertainment

Using force crossed my mind when examining a defiant young patient

Doctor of U.S. President Joe Biden says he is fit for duty

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Dems pitch expanding Medicare power to negotiate drug prices

Biden warns of ‘dark winter’ during final presidental debate

Using force crossed my mind when examining a defiant young patient

focus

explore

entertainment

Wikipedia